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Abstract
The dynamics of the cellular proportion of mutant mtDNA molecules is crucial for mitochon-
drial diseases. Cellular populations of mitochondria are under homeostatic control, but the
details of the control mechanisms involved remain elusive. Here, we use stochastic model-
ling to derive general results for the impact of cellular control on mtDNA populations, the
cost to the cell of different mtDNA states, and the optimisation of therapeutic control of
mtDNA populations. This formalism yields a wealth of biological results, including that an
increasing mtDNA variance can increase the energetic cost of maintaining a tissue, that
intermediate levels of heteroplasmy can be more detrimental than homoplasmy even for a
dysfunctional mutant, that heteroplasmy distribution (not mean alone) is crucial for the suc-
cess of gene therapies, and that long-term rather than short intense gene therapies are
more likely to beneficially impact mtDNA populations.
Author summary
Mitochondria, best known for their role in energy production, are crucial to the survival
of most of our cells. To respond to energetic demands and mitigate against mutational
damage, cells control the mitochondrial populations within them. However, the character
of these control mechanisms remains open. As experimental elucidation of these mecha-
nisms is challenging, theoretical approaches can help us understand the general principles
of cellular control of mitochondria in physiology and disease. Here, we use stochastic
modelling to compare control strategies by studying their impact on the dynamics of
mitochondrial DNA (mtDNA) populations as well as their energetic burden to the cell.
We identify optimal strategies for the cell to control against mtDNA damage and preserve
energy production and use this theory to explore the action of recently developed mito-
chondrial gene therapies, which reduce the fraction of mutant mtDNA molecules inside
cells. We show how treatment efficiency may depend on pre-treatment distributions of
mutant and wildtype mtDNA molecules: treatments are less effective for tissues consisting
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of cells with highly varying mutant levels, and long-term, rather than short intense, gene
therapies should be favoured.
Introduction
Most human cells contain 100-10,000 copies of mitochondrial DNA (mtDNA) which are situ-
ated inside the mitochondria. The proteins encoded by mtDNA are crucial for mitochondrial
functionality, and mutations in mtDNA can cause devastating diseases [1–6]. Heteroplasmy,
the proportion of mutant mtDNA molecules in a cell, typically has to pass a certain threshold
(* 60-95%) before any biochemical defects can be observed [7–14]. The existence of thresh-
olds at which mutant loads begin to have an effect has profound implications for our under-
standing of disease onset, drawing attention to the variance dynamics of the mutant fraction in
cellular populations. As this variance increases more cells can be above threshold, and thus
show pathology, even if average mutant load is unchanged.
Mitochondrial biogenesis and maintenance require cellular resources, and mitochondria
are key sources of ATP and play other important metabolic roles. The particular ‘effective cost’
that cellular control of mitochondria acts to minimise remains poorly understood: for exam-
ple, both decreases [15] and increases [15, 16] in wildtype copy numbers have been observed
for different mutations as the mutant load increases. Some studies suggest that mtDNA density
is controlled [17–19], others that total mtDNA mass [20, 21], or mtDNA transcription rate
[22] is controlled. Understanding mtDNA population dynamics inside cells, and how these
populations react to clinical interventions, is crucial in understanding diseases [23, 24]. How-
ever, experimental tracking of mtDNA populations over time is challenging, necessitating pre-
dictive mathematical modelling to provide a quantitative understanding.
In parallel with efforts to elucidate cell physiological control, protein engineering methods
to artificially control mtDNA heteroplasmy are making fast progress. Two recently developed
methods for cleaving DNA at specific sites involve zinc finger nucleases (ZFNs) and transcrip-
tion activator-like effector nucleases (TALENs) [25–31], which have been re-engineered to
specifically cleave mutant mtDNA [32–36]. MitoTALENs have been successfully used to
reduce mutant loads in cells containing disease-related mutations, but elimination of the target
mutant mtDNA was not complete [32, 37]. Similarly, treating cells multiple times with
mtZFNs led to near-complete elimination of mutant mtDNAs [35, 36]. Quantitative theory for
these therapeutic technologies has not yet been developed, leaving open questions about how
these tools can be optimally deployed.
In this paper, we develop theory from bottom-up bioenergetic principles which allows us to
study the effects of distinct cellular mtDNA control strategies, to analyse the bioenergetic cost of
different mtDNA states, and to combine mtDNA control and energy-based cost to identify opti-
mal control strategies for the cell. Finally, we construct a model for therapeutic mtDNA control
using recent experimental data [36] and highlight challenges linked to heteroplasmy variance.
Results
Control: General insights on the role of feedback control
We employ a linear form of mtDNA feedback control and assume each mtDNA molecule
replicates and degrades according to Poisson processes with rates λ and μ, respectively.
Because control of biogenesis or autophagy yield similar behaviours [38], we assume that the
degradation rate μ is constant and that feedback control is manifest through the replication
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rate λ(w, m), where w and m denote the number of mutant and wildtype mtDNA molecules in
the cell. To connect with experiments, we use μ� 0.07 day−1 corresponding to a half-life of
about 10 days [39]. We only model post-mitotic cells, though our analysis can be extended to
include cell divisions.
Specifically, we use a birth rate of the form:
lðw;mÞ ¼ mþ c1ðwopt   ðwþ dmÞÞ ð1Þ
where c1 > 0, wopt> 0 and δ are constants, with wopt denoting the steady state value towards
which the effective population, here defined as w + δm, is controlled. The magnitude of c1
determines how tightly the population is controlled. We use the term ‘mitochondrial sensing’
to describe how the cell might sense the mitochondrial population that is present. ‘Mutant
sensing’ then refers to how strongly mutants are sensed relatively to wildtypes, which is
encoded in the parameter δ. When steady state is reached (i.e. w + δm = wopt), replication and
degradation rates are equal. In the absence of mutants, the resulting wildtype steady state is
assumed to be optimal. We note that assuming the existence of wopt does not imply a control
based on copy number. Other quantities related to mitochondria may be controlled instead,
such as total mitochondrial mass or ATP production, their desired values being reached at an
effective population size of wopt. Thus, we define ‘mitochondrial sensing’ to refer to a wide
range of mechanisms available to the cell to infer properties of its mitochondrial population,
which can then be used to decide on a control action.
The deterministic dynamics resulting from this control are described in Eq (4). We do not
include the possibility of de novo mutations but our approach can straightforwardly describe
the subsequent behaviour if new mutations arise. Our linear model shares features with the
‘relaxed replication model’ [40, 41] (Eq (5)), though is written in a simpler form. The relaxed
replication model has been used in a variety of other models [42, 43] and has obtained experi-
mental support [15].
We will first investigate properties of more general control strategies, after which we return
to our linear control and discuss parameterisations that optimise the energy status of the cell.
Finally, we use the linear control to fit recent experimental data involving treatment of hetero-
plasmic cells with mtZFNs.
A wide range of control strategies induces similar mtDNA behaviour and admits quan-
titative analysis. Many possible control strategies can be parameterised to give rise to nearly
identical means and variances for wildtype, mutant, and heteroplasmy dynamics up to long
times (e.g. a human life-time) (Fig 1A, 1B and 1C, S1B, S1C and S1D Fig). This is especially
true when mtDNA copy numbers fluctuate around their steady state values, in which case a
linear control forms a good first order approximation to the complex ‘true’ control function.
In this case, it is not the manner in which the controlled quantity is being controlled, but
which quantity is controlled that is the most important. For example, the extent to which
mutants and wildtypes contribute to the replication feedback function (determined by δ)
determines how their relative means and variances evolve (Fig 1D), and contains more infor-
mation on the dynamics than the functional form of λ(w, m) for fixed δ (e.g. whether λ(w, m)
is linear or quadratic).
We stress the difference between two types of average heteroplasmy, as was also
stressed in Ref. [41]: the individual cellular mean heteroplasmy hhicellular ¼ 1ncells
X
cells i
mi
miþwi
(with ncells the number of cells in the tissue) and the tissue homogenate heteroplasmy
hhihomog ¼ ð
X
cells i
miÞ=ð
X
cells i
ðmi þ wiÞÞ. This difference is clearly seen in Fig 1C. When no
explicit selection is present for either mtDNA species, mean cellular heteroplasmy remains
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constant at its initial value m0/(m0 + w0), where w0 and m0 denote the initial wildtype and
mutant copy numbers, respectively. The homogenate heteroplasmy at long times is given by
m0/(m0 + δw0) (section 2.2 in S1 File). It is clear that when mutants contribute little to the
feedback control (small δ), tissue homogenate heteroplasmy can reach high values, and even
approach hhihomog = 1, without explicit selection. A tissue can thus appear, when studying
the homogenate heteroplasmy, to show selection for one type of mtDNA over another,
whereas in fact mean cellular heteroplasmy is unaltered and mutant and wildtypes have
identical proliferation rates.
Nonlinear cost functions predict changes in tissue maintenance. The birth-death model
used to describe mtDNA dynamics can be written as a master equation (Methods, section 1 in
S1 File). S1 Table shows the first order solution of the system size expansion, an approximation
method to master equations, which is known as the linear noise approximation (LNA). Apply-
ing this approximation to a general form of mtDNA control (section 1 in S1 File), we find that
i) if only one species is controlled, the variance of this species quickly reaches a constant value
(see also [38]), ii) when both species are controlled with equal strength their variances increase
at identical rates, iii) in general the more tightly controlled species has a more slowly increasing
variance, and iv) the rate of increase of heteroplasmy variance depends, to first order, only on
mtDNA copy number and turnover (as found in [38]) (Fig 1, Table 1(I)). Eventually, all vari-
ances reach a constant value due to fixation.
Fig 1. A-C: A wide range of cellular control strategies can yield similar dynamics. Stochastic simulations were used to compare three structurally distinct cellular
controls (see legend), each reflecting a different function of the underlying sensed quantity w + δm with δ = 0.5. All controls are set to have the same wildtype mean and
variance in the absence of mutants (section 2 in S1 File). No explicit selection for either mtDNA species is used. Figure (C) illustrates the difference between cellular
mean and tissue homogenate heteroplasmy. D: Control tradeoffs are required when multiple species are present. The more strongly one species is controlled, the
more control is lost over the other. Changes in variances between cells as described by the linear noise approximation (section 1 in S1 File) are shown (intermediate
times). For long times, fixation occurs and the variance of the surviving species saturates. In the most-right figure we depicted the case in which mutants contribute less
to the control than wildtypes (δ< 1).
https://doi.org/10.1371/journal.pcbi.1007023.g001
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What are the biological implications of these findings? A given mtDNA state (w, m) will
accrue a cost to the cell, denoted by C(w, m), which can e.g. be an energetic cost or some other
metric of tissue burden. If this cost function is nonlinear, increasing variances in w and m can
lead to changes in mean cost hC(w, m)i even when mean cellular copy numbers hwi, hmi
remain constant (Methods) because the mean of a nonlinear function of random variables is
not generally equal to the function of the mean of those variables (as seen above with cellular
vs homogenate heteroplasmy). Therefore, the mean cost of maintaining a tissue may increase
over time, even if tissue demands and mean mtDNA levels stay constant (Table 1(II)). How-
ever, these increases may be small and their significance depends on the details of the cost
function: hence the need to consider explicit forms, as we do in the next section.
Cost: An effective mitochondrial energy-based cost function
Next, to find general quantitative principles underlying mitochondrial energy budgets, we
build a cost function that assigns a cost to any given mtDNA state (w, m) and allows a general
quantitative investigation of the tradeoffs in maintaining cellular mtDNA populations. The
‘true’ energy budget of a cell with a given mitochondrial population is highly complex, involv-
ing many different metabolic processes in which mitochondria are involved [44–46]. We pro-
vide a simpler description, focussing on ATP production as a central mitochondrial function,
and removing kinetic details in favour of a coarse-grained representation, to provide qualita-
tive rather than quantitative results.
General cost function structure. Three important terms involved in the energy status of
a cell are: i) the energy demand D, ii) the net energy supply S, and iii) the efficiency of energy
supply. Here we define efficiency as the amount of energy produced per unit of resource con-
sumed. We included intuitive and general terms in our energy-based cost function, such as
Table 1. Key results.
Key results presented in this paper.
I If only one mtDNA species is controlled the variance of the controlled species reaches a constant value. When
both species are controlled with equal strength their variances increase at identical rates, and, in general, the
more tightly controlled species has a more slowly increasing variance (Fig 1). [D]
II The mean energetic cost of maintaining a tissue can increase over time due to the nonlinear influence of
mtDNA variance, even if the energetic demand on the tissue stays the same and mean levels of mtDNA are
constant (Eq 6). [D]
III Intermediate heteroplasmy states can be more expensive than states homoplasmic in either mutant or
wildtype. [C]
IV A control lacking any mutant contribution can show an exponentially increasing cost, and the effects of
particular cellular control strategies are more pronounced in low copy number cells (Fig 3A and 3B). [D, C]
V Control strategies based on the energy status of the cell can often outperform control based on mtDNA copy
number or sensing mtDNA mass (which would work well for deficient deletion mutants, but would be
suboptimal for deficient point mutations) (Fig 3C). [D,C]
VI Even for pathological mutants, reduction of mutant mtDNA alone is not always the optimal control strategy
for a cell to adopt (Fig 4). [C]
VII Tissues with high mean heteroplasmy levels will generally be harder to treat with mitochondrially targeted
endonucleases if the heteroplasmy variance is high, especially if this high mean level is caused by a small
percentage of cells (Fig 6A and 6B). [D,T]
VIII Weak long-term rather than short intense endonuclease treatments are more likely to beneficially impact
mtDNA populations (Fig 6D and 6E). [D,T]
Here we present key results of this paper, which hold under the assumptions used in our models (see text and
Discussion). We place in square brackets the models we invoke for each part: D—our model for mitochondrial
dynamics; C—a particular illustrative family of cost functions; T—a model for gene therapy.
https://doi.org/10.1371/journal.pcbi.1007023.t001
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replication, degradation and maintenance costs, supply and demand, and resource availability.
We seek a cost function that captures the idea that there might be an optimal number of mito-
chondria: not so few that each mitochondrion is inefficiently overworked and not so many
that the burden of the mitochondrial population is itself large.
We express our effective cost function as:
Cðw;mÞ ¼ jD   Sðw;mÞj þ aðwrw þmrmÞ ð2Þ
where α is a scaling constant, and ri gives the rate of resource consumption of a mitochondrion
of type i (w or m). The second term assigns a cost to the use of resource. The terms in this cost
function are expressed as rates: S and D correspond to net energy production (supply) and
demand per unit time. Supply and demand terms are left deliberately generalisable to encom-
pass the differences in metabolic poise between cell types. The demand can be considered to
represent energy requirements of all cellular processes besides mitochondria (whose mainte-
nance costs are incorporated in their net supply S(w, m)), which we assume to be constant. We
are therefore modelling post-mitotic cells in stable environments, as demands are expected to
change throughout the cell cycle. This cost function can be evaluated for any state (w, m) and
assigns the lowest cost to a state that satisfies demand in the most efficient way.
The net energy production of a state (w, m), S(w, m), is modelled as
Sðw;mÞ ¼ wðsðrwÞ   r1Þ þmð�2sð�1rwÞ   r1Þ   ðwþmÞðr2lþ r3mÞ ð3Þ
where ρ1,2,3 are mitochondrial maintenance, building, and degradation costs, s(rw) denotes the
power production (in ATP/s) of a single wildtype mitochondrion given a resource consump-
tion rate rw (Methods, section 4 in S1 File), and λ and μ (which can be functions of w and m)
denote the birth and death rates in units per second. Mutant mtDNA molecules are distin-
guished by the parameters �1, �2 2 [0, 1] describing the mutant resource uptake rate (�1) and
efficiency (�2) relative to that of the wildtypes (rm = �1rw). A low �1 could represent reduced
flow through the electron transport chain due to e.g. damaged respiratory complexes, whereas
a low �2 could denote increased proton leakage. Many mutants are known to have dysfunc-
tional respiratory chain complexes [47], likely causing reduced electron flow through the respi-
ratory chain and therefore reduced consumption rates of respiratory substrates such as NADH
and oxygen. We therefore use �1 < 1 and �2 = 1 as our default choice (further described in sec-
tion 4.7 in S1 File), though settings with �2 < 1 are also investigated (section 5 in S1 File).
The more detailed structure of our cost function, which has been relatively general so far,
comes from specifying the relation s(rw). In other words, how does the energy output of a
mitochondrion depend on its resource (e.g. oxygen) consumption rate? We consider two pos-
sible forms for this function (section 3 in S1 File): a linear output relationship, suggested by
some literature [48–50], and a saturating relationship, which accounts for finite resource con-
sumption and spare mitochondrial capacity [51, 52] (section 5 in S1 File). We refer to these
alternatives as the ‘linear output model’ and the ‘saturating output model’. Both models are
described in more detail in our Methods section (Eq 7).
A trade-off between yield (efficiency) and rate of ATP production is present in yeast [53–
55] whose rate of ATP production due to respiration can become saturated at high resource
levels or limited oxygen supply [53, 56]. Higher energy production rates can then still be
obtained by using fermentation at the expense of a lower yield [53]. A similar trade-off may
exist in mitochondria, whose power production efficiency is higher when oxidizing NADH
compared to oxidizing succinate [50]. The former may be the preferable substrate due to its
higher yield, but if its levels become limiting an increase in the relative use of succinate would
lower overall efficiency. When oxygen is limiting, increased glycolysis in an attempt to increase
Energetic costs and control of mitochondrial DNA populations
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ATP production also leads to lower overall efficiency. These mechanisms could be the cause of
a reduced power production efficiency at high energy demand, as proposed in our saturating
output model. We will contrast our findings of the saturating output model with those gener-
ated by the linear output model.
We fitted the parameters of the linear output model using data provided in Ref. [48] (sec-
tion 3 in S1 File), and set the parameters of the saturating model such that the two models
behave similarly at low ri. Further details on the choice of parameter values, and their bio-
chemical interpretations, are given in section 4 in S1 File; default values are provided in S2
Table. For a given demand D we find the rw which gives a demand-matching supply (details of
the scenarios when supply cannot meet demand are given in section Methods). Given rw we
calculate rm (using rm = �1rw) and so calculate the cost C(w, m).
In taking both the linear and saturating output models into consideration we have endeav-
oured to build the most general picture of a mitochondrial cost function that retains bottom-
up interpretability. Where possible, we estimate associated parameter values based on experi-
mental data. However, other cost function choices are certainly possible and can be analysed
using the platform we present below: our objective here is to complement the generic result
regarding cost functions in paragraph “Nonlinear cost functions predict changes in tissue
maintenance.” with a specific reasonable choice of cost.
Intermediate heteroplasmies may be inefficient and resource availability can dictate the
cost of mtDNA states. Fig 2 shows heatmaps of the cost function in (w, m)-space for differ-
ent mutant pathologies (modelled as different values of �1). Our cost function generates a het-
eroplasmy threshold, its value depending on both wopt and δ, above which demand cannot be
satisfied using oxidative phosphorylation (Fig 2), though increased glycolysis may still main-
tain cell viability. The threshold effect is an established phenomenon in mitochondrial physiol-
ogy [7–14].
The state with lowest cost according to the linear output model is one with a minimum
number of mitochondria required to satisfy demand (Fig 2C), where these mitochondria
respire as fast as possible. This would mean that this state of lowest cost has no spare capacity.
Assuming a cell controls its mitochondrial population towards the state with lowest cost, the
linear model predicts cells to lack spare capacity, contradicting experimental observations
Fig 2. Intermediate heteroplasmies can be less efficient than either wildtype or mutant homoplasmy. A visualization of the cost function in (w, m) space is shown for
both saturating and linear output models, for various mutant pathologies (described by �1). For visualization purposes, states in which cellular demand cannot be
satisified are shown in white. Cells in these states may still survive by e.g. increasing glycolysis (effectively reducing mitochondrial demand). This figure assumes high
copy numbers, results are qualitatively similar for low copy numbers. The actual cost values (given by the colour map) are of lesser importance for our findings, we rather
focus on the qualitative shape of the cost function. A: The magenta (solid) and black (dashed) lines show the contour of the demand-satisfying region when demand is
increased by 10%, or demand is increased by 50% and cellular resource availability is increased by 35%, respectively. B: The orange line corresponds to constant total
copy number; moving up along this line increases heteroplasmy. Cells in region 1 or region 3 are more efficient, and show a lower cost, than cells in region 2. C: The
linear mitochondrial output model does not show a decreased efficiency at intermediate heteroplasmy values.
https://doi.org/10.1371/journal.pcbi.1007023.g002
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[51, 57, 58]. A saturating output model solves this problem (S2E Fig and Fig 2A and 2B) and
generates a trade-off between using each mitochondrion efficiently (minimising its resource
consumption by increasing population) and minimising the cost of maintaining the total
number of mitochondria (achieved by reducing the population). At low resource consump-
tion, representing the linear regime of the saturating output model, the two models are
similar.
We observe other qualitative differences in cost function structure between the saturating
and linear output models. In the former, it is possible for intermediate heteroplasmy states to
be more expensive than states homoplasmic for either species (Fig 2A and 2B). Hence, in the
saturating output model, it is possible for intermediate heteroplasmies to be the least efficient
and the most expensive (Fig 2 and S4 Fig, Table 1(III)). This result arises from a tradeoff,
when mutant load is increased, between a decrease in global efficiency and a reduction in
resource consumption by the new mutants (section 5 in S1 File). The linear output model, on
the other hand, always shows higher costs at higher heteroplasmy (for fixed total copy number)
(Fig 2C).
For our cost function, the existence of a high-cost intermediate heteroplasmy value is a rela-
tively general feature of the saturating output model. We calculated the value of heteroplasmy
with maximum cost (at constant total copy number), denoted by hmax, as a function of several
model parameters. hmax = 1 (the homoplasmic mutant state) at values �1≲ 0.3 due to very low
mutant functionality. However, at higher values of �1 (0.5≲ �1 < 1) we find hmax* (0.5–0.8)
over a large range of several of our cost function parameters (section 5.2 in S1 File). Though
the size of the effect may be small, its existence alone is an interesting feature of our saturating
output model.
It was previously found that it is possible for two mtDNA variants in mice to function nor-
mally at homoplasmy, but show deficiencies in heteroplasmic states [59]. While we do not
claim that our model is the reason behind these observations it does suggest that differing
resource consumption rates associated with distinct mtDNA species may play an important
role.
Combining cost and control: Comparison and optimisation of both cellular
control and treatment strategies
Timescales and energy sensing in optimal control of mtDNA populations. Here we
compare the mean cost over time for four plausible cellular control strategies. The first two
consist of the linear feedback model λ(w, m) = μ + c1(wopt − (w + δm)) with (I) δ = 0 (only
wildtypes are sensed) and (II) δ = 1 (total mtDNA copy number is controlled). We further
identify optimal parameterisations (i.e. ones that minimise steady-state cost) of two control
strategies, namely (III) a linear feedback control and (IV) the ‘relaxed replication model’
(Eq (5)) [40, 41].
First, we fix the parameter values that are not being optimised. Our goal is to compare the
costs of the dynamics resulting from each of the four controls, in the presence of mutants. In
other words, we want to investigate whether some of these controls are better at protecting the
cell (in the sense of maintaining a low energy cost) against mutant loads than others. To make
this comparison fair, we demand that all controls yield the same dynamics in the absence of
mutants: we set the wildtype mean and variance in this case to be identical under all controls.
The mean is chosen to be wopt (assuming that, without mutants, each control steers the popula-
tion of wildtypes to its optimal value) and the variance is set by fixing the parameter αR in the
relaxed replication model to αR = 10 (Eq (5)), as its value was originally estimated to lie in the
range (5–17) [40]. This fixes the value for c1 in models (I)-(III) (S3 Table).
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We now wish to optimise the parameters δ and η in models (III) and (IV). These parame-
ters have direct impact on how mutants are sensed by the cell, and are important in determin-
ing how the dynamics change when mutant load increases. We thus want to investigate i)
whether there exists an optimal amount of mutant sensing, and ii) how the cost of the dynam-
ics resulting from these optimal parameters δopt and ηopt compares to that of our other two
control strategies with δ fixed at either 0 or 1. To do this, we require both an optimization
time-scale T and a set of initial conditions. We use T =1, corresponding to the steady state
limit, and initial heteroplasmy values in the range h0 2 [0, 0.2]; we later consider finite values
of T.
Through stochastic simulations, we find that i) a control lacking any mutant contribution
shows an exponential increase in cost over time, and ii) effects of particular control strategies
are more pronounced in low copy number cells (Table 1(III)) (Fig 3). The relaxed replication
rate control and our linear feedback function behave very similarly when δ and η take their
optimal values. Cost variances, as well as mutant and wildtype dynamics, are shown in S6 Fig.
Model II shows an increase in mean cost over time while mean mutant and wildtype copy
numbers remain constant (Fig 3 and S6 Fig)—this is due to increases in copy number vari-
ances as argued previously.
We now investigate how the optimal value of mutant sensing for the linear control (δopt)
depends on timescale T, initial heteroplasmy h0 and the ‘mutant pathology level’ described
by �1. Here, we use the term ‘mutation pathology level’ to refer to a lower energy production
rate of mutants due to a lower resource consumption rate, while ‘mutant sensing‘, as
explained earlier, is used as a more general term. Intuitively, values of �1’ 1 have δopt� 1:
when wildtypes and mutants are equivalent, having a steady state with w + m = wopt is
desirable.
Values for δopt were found for the linear and saturating models, with low and high initial
heteroplasmy values, for T = 100 days (Fig 3C). Having δ� 1 means wildtypes and mutants
are fed back similarly, whereas when δ� 1 mutants are fed back less. For very deficient
mutants (low �1), a low δopt ensures that wildtype copy number remains close to its optimal
value to compensate for the mutants. Generally, as �1 decreases, δopt decreases (Fig 3C). Similar
results are found for longer timescales T (section 5.3 in S1 File).
Fig 3. A control that senses no mutations shows an exponentially increasing cost, which is most noticeable in low copy number cells. A + B: Here we show the mean
cost (3 × 104 repeats) for the following four controls: linear feedback controls λ(w, m) = μ + c1(wopt − (w + δm)) with I) δ = 0, II) δ = 1, and III) δ = δopt, and IV) the
optimised ‘relaxed replication control’ [40, 41] (Eq (5)). Controls were initialised in steady state at h0 = 0.15. Both figures used the saturating output model; figures (A)
and (B) correspond to low and high copy number cells, respectively. We used �1 = 0.3; other control parameters used are specified in section 5.3 in S1 File. C: A control
based on sensing mitochondrial energy output is generally a good strategy. This plot shows the optimal value of δ in our linear control as a function of �1, for the linear
and saturating model and for both low (h0 = 0.1, solid line) and high (h0 = 0.8, dashed line) initial heteroplasmies. Here we used T = 100 and high copy number values for
both models. Similar plots for T = 104 are shown in S7 Fig, section 5.3 in S1 File. In the linear model δopt becomes negative for low �1 values; as mutant copy number
increases, a negative δ leads to an increase in wildtype to compensate for the deficient mutants.
https://doi.org/10.1371/journal.pcbi.1007023.g003
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If mitochondrial energy outputs are sensed, the quantity ‘w + δm’ represents the mitochon-
drial energy production rate (power production). In this case, a mutant with low �1 produces
less energy and is thus sensed less (low δ). The relation between �1 and δ now obeys the optimal
trend shown in Fig 3C. Therefore, control strategies based on the energy status of the cell can
often outperform controls based on mtDNA copy number (which always have δ = 1) or sens-
ing mtDNA mass (which would work well for deficient deletion mutants, but would be subop-
timal for deficient point mutations) (Table 1(IV)). Control based on copy number is preferred
when a mutant is nearly as functional as a wildtype, in which case energy output and copy
number are very much related. We have not used the expression for energy output in our cost
function as a control strategy itself because claims based on the linear function w + δm are
more general than one based on the details of our cost function.
Locally optimal control strategies map the control space of mtDNA populations. Our
cost function allows us to identify locally optimal controls: controls that, for each state (w, m),
move the system in the direction of the largest decrease in cost. The resulting dynamics are
shown in Fig 4. When heteroplasmy is high, the main priority is not always to decrease mutant
copy number, but to increase wildtype copy number even if this means an increase in mutant
load (region 2 in Fig 4A). Only after wildtype copy number has sufficiently increased should
the focus be on decreasing m. At high copy numbers, the optimal dynamics are to decrease all
mtDNA in an evenhanded manner (region 1) rather than decreasing m at a faster rate than w.
For the saturating model, there is a divergence point in the space of local optimal strategies,
reflecting the two local cost minima (high wildtype and high mutant) observed earlier (Fig 2).
Hence, there are several regions of state space where even for pathological mutants, reduction
of mutant mtDNA alone is not always the optimal control strategy (Table 1(V)). Finally, the
less pathological the mutants become (e.g. Fig 4B), the more the locally optimal control starts
to resemble a linear control. In the linear output model, the optimal control always shows lin-
ear behaviour (Fig 4C).
A parameterised model of artificial mtDNA control for disease treatment. In the previ-
ous section we identified locally optimal control strategies. Of course, these strategies may not
be achievable by the cell (e.g. the cell may not be able to decouple biogenesis of wildtype and
mutant mtDNA). However, such controls may still be possible through human intervention.
Fig 4. Locally optimal controls show nonlinear behaviours close to demand-satisfying regions, but linear optimal dynamics far away from these regions.
Streamplots in (w, m)-space show the dynamics resulting from a locally optimal control, for various parameters of �1. At each point, arrows show the direction
corresponding to the largest decrease in cost. Regions are coloured according to the magnitude of the decrease in cost when moving in the optimal direction. Black
arrows illustrate general trends in these regions. A: Region (1) shows that at high copy numbers, both mutant and wildtype mtDNAs should be decreased in an
evenhanded manner; region (2) shows the possibility that the optimal control involves an increase in mutant copy number. B: A higher value for the parameter �1 is
used, meaning mutants are less pathological. C: the locally optimal control for the linear output model more closely resembles a linear control. In both (A) and (B)
we see a divergence point (red asterisk) illustrating the fact that both high mutant and high wildtype states constitute local attractors of low cost (as in Fig 2).
https://doi.org/10.1371/journal.pcbi.1007023.g004
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This is why, in this section, we model recently developed genetic treatments to artificially con-
trol mtDNA populations. We then combine this treatment model with our linear feedback
control λ(w, m) and our cost function.
Mitochondrially targeted zinc finger nucleases (mtZFNs) [35, 36, 60–62] are able to pro-
duce shifts in heteroplasmy by specifically cutting mutant mtDNA. To develop quantitative
theory to understand and tune the effects of these interventions, we model nuclease transfec-
tion as inducing selective increases in mtDNA degradation, on the background of the linear
cellular feedback control introduced earlier. Our transfection model contains three parameters
describing strength (I0), duration (b), and selectivity (ξ) of nuclease treatment (Methods). We
assume that for every mutant that is cleaved by the endonucleases, ξ wildtypes are cleaved [36].
For example, when ξ = 1 there is no distinction between mutants and wildtypes, and when ξ =
0 there is no off-target cleavage.
We fit these treatment parameters, as well as our feedback control parameters c1 and δ, to
recently obtained experimental data [36]. These data involve heteroplasmy and mtDNA copy
number measurements during iterative treatments with mtZFNs of 80% heteroplasmic human
osteosarcoma 143B cybrid cells. Four sequential cycles of transfection and recovery were per-
formed, where each recovery period lasted 28 days [36]. We use the data provided in Ref. [36]
as well as additional data from this reference which was not explicitly provided in the paper.
For the current study, we have collected new data consisting of: i) measurements of total
mtDNA copy number in pre-treatment cells (which are used as initial conditions in our infer-
ence model), and ii) measurements of mtZFN expression profiles (S9 Fig).
A Bayesian description of nuclease treatment. We use Metropolis sampling to obtain
posterior distributions of the parameters I0, b, ξ, c1 and δ (Methods). Bayesian credible
intervals for heteroplasmy and total copy number values during four consecutive rounds of
treatment are shown in Fig 5A and 5B, illustrating the ability of this simple model to capture
the dynamics resulting from nuclease activity. A periodicity of 28 days was imposed, represent-
ing the experimental protocol (Methods).
Our inference suggests the selectivity parameter ξ to lie in the range 0.6–0.8, indicating high
levels of off-target cleavage (S10 Fig). This is not surprising given the large drop in total copy
number (as low as *5% of initial values) combined with a modest shift in heteroplasmy (from
0.8 to * 0.6) upon the first treatment. Supporting the high off-target cleavage, mtZFNs not
targeted to any mtDNA sequence reduced copy numbers to 25% of their original values [36].
We now investigate whether our model can account for additional data (obtained in
Ref. [36]) consisting of heteroplasmy and copy number measurements in a setting in which
the concentration of mtZFNs is reduced by incorporating hammerhead ribozymes in the
mtZFN backbone (for details, see Ref. [36]). A single round of treatment and recovery in this
setting led to a large shift in heteroplasmy, from h� 0.8 to h� 0.2, and a drop in copy number
similar to the previous setting in which mtZFN concentrations were higher (after 24 hours,
mtDNA copy number dropped to*20% of its original value) [36]. These observations indi-
cate that lower mtZFN concentrations lead to the treatment being more selective and, surpris-
ingly, of similar strength. Because the additional data involves a different experimental setup
inducing a large increase in selectivity, we adjust the parameter ξ to fit this additional data by
finding its maximum likelihood estimate (Methods) but use posterior samples for all other
parameters (obtained from inference based only on the data shown in Fig 5A and 5B). We
find, consonant with an improved selectivity of this modified protocol, that ξ� 0.15 in this
low mtZFN concentration setting (Methods) and that our model can reproduce the hetero-
plasmy and copy number dynamics using our previously fitted parameters I0, b, c1 and δ
(Fig 5C and 5D).
Energetic costs and control of mitochondrial DNA populations
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007023 June 26, 2019 11 / 27
Finally, we measured transient expression profiles of mtZFNs using the same transfection
protocol as in Ref. [36] (S9 Fig). Posterior samples of the parameters I0 and b predict that
mtZFN levels have dropped to very low levels 5 days post-transfection in the setting without
hammerhead ribozymes, consistent with our obtained experimental data (S11 Fig). We thus
show that our model is capable of capturing the dynamics of several data sets. Our mtZFN
treatment model predicts that total copy number reaches a minimum at around 3 days (Fig 5B
and 5D).
Knowledge of the heteroplasmy distribution of a tissue is important in determinining
how effciently the tissue can be treated. To explore the effect of the heteroplasmy distribu-
tion on treatment efficacy, we consider three initial h distributions with different variances but
identical homogenate means. We treat these populations multiple times using the parameter
fits obtained in the previous section. The resulting shifts in heteroplasmy distribution,
Fig 5. Bayesian credible intervals show the ability of a simple nuclease treatment model to capture experimental observations. We used Metropolis sampling to fit
our model parameters to recently obtained experimental data [36]. Solid black lines correspond to the maximum a posteriori (MAP) prediction and vertical dashed lines
indicate transfection events (once every 28 days). A: Drawing from our posterior distributions (5 × 104 samples), we show the mean and 50% and 95% credible intervals of
our heteroplasmy dynamics predictions during four rounds of treatment and recovery. Deterministic simulations were used. Crosses indicate data points from
Ref. citeGammage16Near. B: Similar to figure (A), but showing relative total mtDNA copy numbers. C + D: Heteroplasmy and copy number dynamics were measured
during a single round of treatment and recovery in a setting in which the mtZFN concentration was reduced by incorporating hammerhead ribozymes in the mtZFN
backbone [36]. The credible intervals shown were obtained by sampling from the posterior distributions of the parameters I0, b, c1 and δ obtained using the data in figures
(A) and (B), and using ξ* 0.15 which represents the maximum likelihood estimate of ξ using this low mtZFN concentration data (Methods). Error bars in figure (D)
show standard deviations of experimental measurements [36].
https://doi.org/10.1371/journal.pcbi.1007023.g005
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including mean and threshold-crossing probability, are shown in Fig 6A and 6B. High hetero-
plasmy variances require many cells close to the two extremes h = 0 and h = 1, which are chal-
lenging to shift. A striking reduction in treatment efficacy is predicted as heteroplasmy
variance increases while fixing its mean (Fig 6A and 6B). Threshold crossing probability (for
example, P(h> 0.6)) also becomes harder to shift at higher variance. We conclude that tissues
with a high mean heteroplasmy level will generally be harder to treat if the heteroplasmy vari-
ance is high, especially if this high mean level is caused by a small percentage of cells.
We can use our parameterised theory to find optimal treatment strengths I0,opt for a given
system. Fig 6C shows I0,opt as a function of �1. Intuitively, the strongest treatment should be
given to the least functional mutants, and when mutants are almost as functional as wildtypes
Fig 6. Knowledge of the heteroplasmy distribution is important in predicting how efficiently a tissue can be treated. A + B: The effect of four simulated consecutive
treatments on three different initial heteroplasmy distributions is shown; all initial distributions have identical means (hhi = 0.8) but different variances (increasing from
left to right). The higher the variance of the initial population, the harder to shift mean heteroplasmy values; mean values after each treatment as well as P(h> 0.6) are
shown in figure (B). In these simulations we assumed that every cell gets transfected. Gentle but sustained treatments induce larger heteroplasmy shifts than hard and
brief treatments. C: Both the linear and saturating model show a sharp drop in the optimal treatment strength I0,opt as the mutants become more functional (i.e. as �1
increases). D: Means and variances of mutant and wildtype copy numbers were simulated during a round of treatment and recovery, using: i) parameters fitted to the
data shown in Fig 5A and 5B (blue), ii) a longer treatment duration (smaller b, green) and iii) a higher selectivity (smaller ξ, magenta). MtZFN levels first drop below 5%
of their maximum values after *4.5 and *35 days for the short (blue, magenta) and long (green) treatments, respectively. The longer weaker treatment induces higher
heteroplasmy shifts than the shorter stronger treatment. �1 = 0.2 was used, the corresponding cost heatmap is shown. Error bars show standard deviations (based on 10
4
stochastic simulations), further detailed are given in section 6.6 in S1 File. E: This figure also illustrates that gentle sustained treatments lead to larger heteroplasmy shifts.
Examples of treatment trajectories are shown; after a single treatment, an initial heteroplasmy of 0.8 is mapped to 0.53 (short strong treatment) or 0.39 (long weak
treatment). Parameters chosen in figures (A)–(E) are based on the inference performed earlier, their exact values are provided in section 6.6 in S1 File.
https://doi.org/10.1371/journal.pcbi.1007023.g006
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it is preferable not to treat at all. The optimal treatment strength drops rather sharply as �1
increases, and does so sooner for the saturating model. This last observation may be because at
some point reducing heteroplasmy becomes more expensive as can be seen in Fig 2B. Optimal
treatment strengths for longer treatments (higher b) show similar qualitative behaviour.
Fig 6D shows trajectories in (w, m) space throughout a single treatment and recovery phase.
The three trajectories shown correspond to: i) a short and strong treatment, ii) a long and
weak treatment, and iii) a short but more selective treatment. The value for I0 was chosen such
that, for the specific treatment duration b used and given a fixed total simulation time, the shift
in heteroplasmy was largest. For the short treatment a relatively large proportion of time is
spent fluctuating around steady state values (dynamics which do not change mean h) due to a
relatively quick recovery, whereas for longer treatments more time is spent in the treatment
phase itself (dynamics which lower mean h). We thus find that in a given time frame, treating
longer but weaker results in a lower final heteroplasmy value than treating short and strong
(Table 1(VIII)). A weaker treatment also reduces the chance of a cell losing all its mtDNA mol-
ecules. Intuitively, a more selective treatment leads to larger heteroplasmy shifts.
Nuclease treatment and a subsequent recovery phase will have the net effect of mapping an
initial heteroplasmy value hi to a mean final heteroplasmy value, hf. We simulated this map-
ping in the presence of cellular feedback control (Fig 6E), finding that heteroplasmy shifts are
largest for intermediate heteroplasmies. The difference in treatment results for long compared
to short treatments is also illustrated. Interestingly, for high h values, it is possible to end up
with a higher heteroplasmy value after treatment, especially if ξ’ 1 (S8 Fig).
Discussion
In this work, we have built a quantitative theory bridging stochastic optimal control, costs of
mtDNA populations, and gene therapies. Our results contribute to a growing body of evidence
[63–66] that the variance of mtDNA populations has important physiological and therapeutic
implications independently of mean heteroplasmy, and underline that stochastic theory is
required to understand this biologically and medically important quantity.
Key findings of our model (Table 1) include (I) the identification of tradeoffs in the control
of one or the other mtDNA species; (II) the observation that increasing mtDNA variance can
lead to increased energetic costs over time and ageing even when means and demands are pre-
served; (III) intermediate heteroplasmy states can be more expensive than states homoplasmic
in either mutant or wildtype; (IV) mutant sensing can be required to avoid an exponentially
increasing cost; (V) sensing of cellular energetic status can be more effective than other targets
like mitochondrial mass; (VI) reduction of mutant mtDNA alone is not always the optimal
control strategy; (VII) high heteroplasmy variance challenges gene therapy treatments; and
(VIII) weak, long gene therapy trajectories are more effective than short, intense ones.
Our findings hold qualitatively under the range of conditions we discuss above. The aim of
our manuscript is not to make detailed quantitative predictions and conclusions based on
complex models, nor do we intend to imply that our models are the only possible models one
could construct. Rather, we aim to provide general biologically plausible models to gain quali-
tative insights and to comment on large-scale behaviours. To this end, our cost function, used
to illustrate some of our results, is phenomenological and contains several parameters. Most of
these are biologically interpretable, meaning their values can be obtained or estimated from
the literature. The main elements in our cost function are quite general: terms involving sup-
ply, demand, and resource.
To test the qualitative shape of our cost function, one could sort cells based on mitochon-
drial copy number and heteroplasmy to obtain samples at different points in (w, m) space.
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Measurements of e.g. cell proliferation, ROS or apoptosis rates allow for the evaluation of an
effective cost at each of these points. By measuring the relative consumption rates of NADH
and succinate, as well as the amount of ATP produced per glucose consumed, in identical cells
exposed to different energy demands, the saturating output model may be probed.
If the parameter δ is low, i.e. mutants are sensed less, mutant copy numbers at high hetero-
plasmies will be higher than wildtype copy numbers at low heteroplasmies. Experimentally, it
has been observed that heteroplasmic cells can have total mtDNA copy number values that are
5-17-fold higher compared to cells homoplasmic in wildtype [67–70]. The cell has somehow
allowed these mutants to expand, which may mean that they are less tightly controlled; con-
trols based on total energy output or mtDNA mass (which can result in δ< 1) may lead to
such behaviours. A control on mtDNA mass could explain why deletion mutants are often
seen to expand [71, 72] and would also predict normal copy number levels in cells harbouring
mtDNA point mutations. Recently, it was found that samples with mtDNA indels had very
high mtDNA copy number levels, but single nucleotide variants did not [73].
We showed that heteroplasmy distributions in cell populations can provide important
information about the possibility of successfully treating these cells with endonucleases. A tis-
sue may be harder to treat if its high mean heteroplasmy level is caused by a small percentage
of dysfunctional cells. Experimental values of mean homogenate heteroplasmy in heart tissue
of patients with the 3243A>G mutation are roughly around 0.8 (though ranges can be large
[74–77]) and muscle tissue often shows mosaic structures, with deficient patches of cells adja-
cent to healthy cells. These examples show that it may be that, at least in some cases, high
mean levels are indeed caused by a relatively low percentage of cells, meaning that there are
still challenges ahead for efficiently treating these tissues.
One of the features of our cost function is that resource limitations play an important role
in shaping the cost landscape. There are indications that cellular levels of NAD (a coenzyme
involved in oxidative phosphorylation) are limiting, and that a sufficient supply of NAD to
mitochondria becomes critical [78–81]. An increase of intracellular NAD can lead to an
increase in oxygen consumption and ATP production [81] indicating that resource limitation
may, at least in some cases, be a genuine constraint. Adding various kinds of resources can sig-
nificantly change mitochondrial basal respiration rate [82–84].
Like any other model, our models have a defined range of applicability. A key baseline
assumption was using identical replication and degradation rates for mutants and wildtypes.
Various possibilities of distinct rates have been offered in the literature, including faster
mutant replication rates [22, 68, 85–88], lower mutant degradation rates [89], and higher
mutant degradation rates [90, 91]. Including such differences, and other features such as de
novo mutations, degradation control, and cell divisions [38, 64, 92, 93], constitute natural
extensions to our theory.
Methods
Wildtype and mutant mtDNA evolution equations
Wildtype and mutant mtDNA copy numbers are considered to have birth rate λ(w, m) = μ +
c1(wopt − (w + δm)) and death rate μ, leading to the following evolution equations:
dw
dt
¼ wðlðw;mÞ   mÞ
dm
dt
¼ mðlðw;mÞ   mÞ
ð4Þ
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The corresponding stochastic system, required to e.g. describe fixation, does not have an
explicit solution due to nonlinearities. The deterministic steady state solution of Eq (4) is given
by (wss + δmss) = wopt and represents a straight line in (w, m)-space (S1A Fig), whose slope
depends on the value of δ. Stochastic dynamics will fluctuate around the steady state line, caus-
ing heteroplasmy to change over time until fixation of either species occurs. This means that,
over long times, a cell will reach either h = 0 or h = 1 (in the absence of mutations). When
mutations do occur, a cell will always reach a state with h = 1 (though many different mutant
species may be present).
Relaxed replication model
The relaxed replication model assumes a constant death rate μ and a birth rate of the form
lðw;mÞ ¼
m
wþm
aR wopt   ðwþ ZmÞ
h i
þ wþ Zm
� �
ð5Þ
with αR> 1 and η constants [40, 41]. We have renamed the parameters of the original model
for convenience. Note that both αR and η influence the mutant contribution to λ(w, m) (rather
than the single parameter δ in our linear model).
Expected cost per unit time
Let the cost per unit time of state (w, m) be denoted by C, and the cost corresponding to the
steady state (wss, mss) by �C. Even if steady state copy numbers are constant over time (i.e. the
mean values of w and m are always equal to wss and mss) the mean cost per unit time is gener-
ally not equal to �C. By performing a Taylor expansion, the mean cost per unit time can be writ-
ten as follows:
E½C�ðtÞ � �C þ
1
2
�
varðwðtÞÞ
@
2C
@w2
þ varðmðtÞÞ
@
2C
@m2
þ2covðwðtÞ;mðtÞÞ
@
2C
@w@m
� ð6Þ
where E[C](t) is the expected cost per unit time given that the trajectory starts in state (wss,
mss), and all partial derivatives are evaluated at steady state. These findings imply the following:
suppose all cells in a population of cells are initialised in a state with minimum cost (corre-
sponding to some specific number of mutant and wildtype mtDNA molecules). At some later
time, the mtDNA populations in the different cells will have drifted apart and even if mean
copy numbers (averaged over all cells) of w and m are identical to their initial values, the
increase in variance between cells means that the overall mean cost (averaged over all cells) is
higher than it was initially.
Cost function structure
We assume that the net energy supply per unit time in a state (w, m), called S(w, m), involves
the following four terms: (i) the energy output per unit time (si) produced by the mitochon-
dria; (ii) a maintenance cost per unit time (ρ1) to maintain the mitochondria, as their presence
imposes some energetic cost (e.g. mRNA and protein synthesis); (iii) a building cost (ρ2) for
the biogenesis of new mitochondria; and (iv) a degradation cost (ρ3) to degrade mitochondria.
We will assume that every mtDNA molecule is associated to a particular amount of mitochon-
drial volume which we refer to as a ‘mitochondrion’ (section 4 in S1 File).
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At any time, mitochondria experience a certain energy demand and to meet this demand
they need to have a certain resource consumption rate ri (where i = w, m refers to wildtype or
mutant). Here we use the term ‘resource’ as an amalgamation of the substrates used for the oxi-
dation system. We need to specify the relationship between the power supply (s) and the rate
of resources consumed (ri) by mitochondria. We use two different models s(ri) which are dis-
cussed further in section 3 in S1 File
sðrwÞ ¼ �ðrw   bÞ
sðrwÞ ¼ 2
smax
1þ e  krw
  1:1smax
ð7Þ
where ϕ, β, k and smax are constants respectively describing the mitochondrial efficiency, a
basal proton leak-like term, the saturation rate of the efficiency, and the maximum power sup-
ply (section 4 in S1 File).
We assume that pathological mutants can have a deficient electron transport chain (which
may support a smaller flux leading to a lower resource consumption rate for mutants and
therefore a lower ATP production rate) and a lower energy production efficiency, leading to
the following mutant energy output: �2s(�1rw). Here, �1, �2 2 [0, 1] describe the mutant
resource uptake rate and the mutant energy production efficiency relative to that of a wildtype,
respectively. In the main text we set �2 = 1; other values of �2 are discussed in section 4.7 in S1
File.
The mitochondrial maintenance cost is denoted by ρ1 and corresponds to the energetic cost
required to maintain the mitochondrion that contains the mtDNA. This energetic costs
involves factors like the synthesis and degradation of mitochondrial proteins and enzymes. We
assume the maintenance cost is the same for wildtype and mutant mitochondria (though for
some mutations this is quite possibly not the case). The net energy supply per unit time, S(w,
m), then follows as Eq 3.
To determine the value of rw for a given state (w, m), we first check whether the demand D
(which we assume is a constant) can be satisfied by supply S(w, m). If it can, we set Eq (3)
equal to D and solve for rw, i.e. we assume that if possible, the mitochondria will exactly satisfy
demand. It may, however, not be possible to satisfy demand, which can be because of two rea-
sons: i) there are not enough mitochondria present to produce enough energy, or ii) the
resource supply rate, R (a constant), is not enough to meet demand. In the former case, we set
rw = rmax (a specified maximum resource consumption rate per mitochondrion): the mito-
chondria work as hard as possible to keep their energy output closest to demand. In the latter
case, we assume that the total available resource supply is shared equally between the mito-
chondria: rw ¼ Rwþ�1m. Further details of the cost function are given in sections 3–5 in S1 File.
The parameters used in our cost function are summarised in S2 Table and motivated in
section 4 in S1 File. Despite our model being simple, most parameters are biologically
interpretable.
Modelling control through mitochondrially targeted endonucleases
Experimentally, cells are transfected with two mtZFN monomers: one which binds selectively
to mutant mtDNAs, and one that binds mutants and wildtypes with equal strength [62]. We
simplify this picture by assuming an ‘effective’ mtZFN pool and use [ZFN] to denote its con-
centration. The increase in mtDNA degradation rate caused by the mtZFNs is then assumed
to be proportional to [ZFN].
Nucleases are imported into the cell and then degrade over time, meaning that their con-
centration in the cell (and in the mitochondria) may be approximated by an immigration-
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death model:
d½ZFN�ðtÞ
dt
¼ IðtÞ   mz½ZFN�ðtÞ ð8Þ
where I(t) and μZ are the immigration and death rates of the effective mtZFN pool, respec-
tively. In recent experiments [36], nucleases are expressed for short times meaning that the
immigration rate will increase sharply at the start of the treatment after which it decreases over
time: we chose to model I(t) as an exponentially decaying function, I(t) = I0e−bt, where I0
denotes the initial rate directly after the treatment is initiated and b is a constant describing the
duration of the treatment. The mtZFN concentration now becomes
½ZFN�ðtÞ ¼
I0
mz   b
e  bt   e  mz t
  �
ð9Þ
which is shown for various parameter values in S8A Fig. The data we use to fit our models con-
cerns heteroplasmy and total copy number measurements over four rounds of treatment, each
treatment consisting of mtZFN transfection followed by a 28-day recovery period. During this
recovery period, total copy numbers recover their initial values due to cellular feedback con-
trol. The increase in mtDNA death rate due to the presence of the mtZFNs, μZFN, is given by
mZFNð28 � i < t < 28 � ðiþ 1ÞÞ ¼ mþ
Xi
j¼0
½ZFN�ðt   28 � jÞ ð10Þ
where i = 0, 1, 2, 3 indicates the treatment round. This equation is simply stating that new
mtZFNs are added every 28 days. Death rates for m and w are now assumed to be
mðtÞw ¼ mþ x � mZFNðtÞ
mðtÞm ¼ mþ mZFNðtÞ
ð11Þ
where μ denotes the baseline degradation rate and ξ represents treatment selectivity (e.g. when
ξ = 0 there is no off-target cleavage).
Model fits using Metropolis sampling
To fit our nuclease model to recently obtained experimental data [36], we use Eq (4) with μ
replaced by μ(t)w or μ(t)m and λ(w, m) given by Eq (1):
dw
dt
¼ w½c1ðwopt   ðwþ dmÞÞ   x � mZFNðtÞ�
dm
dt
¼ m½c1ðwopt   ðwþ dmÞÞ   mZFNðtÞ�
ð12Þ
Total mtDNA copy numbers in pre-treatment 80% heteroplasmy cells were measured
using quantitative PCR (section 6.4 in S1 File) and were found to be 889 ± 214 (S.E., n = 3).
We therefore assume an initial total copy number of 900, meaning w and m were initialized at
0.2 � 900 = 180 and 0.8 � 900 = 720, respectively. These evolution equations incorporate cellular
feedback control as well as the nuclease treatment which occurs in cycles of 28 days. The
mtZFN degradation rate was assumed to be μz = ln(2) day−1, corresponding to a half-life of 1
day. This is in accord with the experimental observation that almost no mtZFN was present 4
days post-transfection (with a half-life of 1 day, only 6% of initial copy numbers remain after 4
days).
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MCMC inference was performed using the Python package Pymc3, a package designed for
Bayesian statistical modelling and probabilistic machine learning [94]. A Gaussian error model
was assumed, i.e. the observed heteroplasmy yðhÞi and total copy number y
ðTÞ
i data are given by
yðhÞi ¼ y^
ðhÞ
i þ Nð0; s2hÞ
yðTÞi ¼ y^
ðTÞ
i þ Nð0; s2TÞ
ð13Þ
where y^ðhÞi and y^
ðTÞ
i denote our predicted heteroplasmy and copy number values obtained by
numerically solving Eq (12), and we allow for different noise variances for h and T (in general,
different experimental errors are expected as different methods are used to measure h and T). A
metropolis sampler is used for parameter estimation. Maximum a posteriori (MAP) values were
found to be ðI0; b; c1; x; d;s2h; s
2
TÞMAP � ð122:82; 46:68; 1:90� 10
  4; 0:72; 1:26; 0:061; 0:10Þ.
Due to a degeneracy in our mtZFN dynamics model (section 6.5 in S1 File) the MAP values of
I0 and b are not necessarily unique at large b (details in section 6.5 in S1 File).
We explore the ability of our model to account for additional data from Ref. [36] (Fig 5C
and 5D) which was not included in our inference. Using the MAP values for parameters I0, b,
c1, δ, s2h and s
2
T (based on the data shown in Fig 5A and 5B), the maximum likelihood estimate
of ξ is obtained based on the additional data, using a Gaussian error model similar to Eq (13).
This maximum likelihood value is ξ� 0.15.
Supporting information
S1 Fig. A linear feedback control has straight steady state lines. A) The deterministic steady
state lines of the feedback control given in Eq 4, using our linear version of λ(w, m), are shown
in (w, m) space for various values of δ (grey lines show particular examples of ranges of δ).
Constant heteroplasmy lines form straight lines through the origin. B, C, D) Equal variances
for different feedback control mechanisms. Three different controls (see legend), all of the
form λ(w + δm) with δ = 0.5, show nearly identical wildtype, mutant and heteroplasmy vari-
ances. Other parameters used are Nss = 1000 (referring to the steady state copy number present
in the absence of mutants), μ = 0.07 (corresponding to a half-life of 10 days), and initial copy
numbers (w0, m0) = (920, 160) (corresponding to an initial heteroplasmy of * 0.15).
(EPS)
S2 Fig. Relationship between resource consumption and energy output. A) The energy pro-
duction rate of a single wildtype mitochondrion as a function of its resource consumption rate
is shown, as given by Eqs. (15) and (16) in S1 File. For the linear model (corresponding to the
straight lines) the parameters ϕ and β are changed by 10%, for the saturating model we vary
smax and k. The magenta line indicates rmax. B) As w increases, demand is shared between
more mitochondria and each individual one can afford to consume resources at a lower rate
(the same figure legend applies for figures C, D and E). C) The total resource consumption
increases with w because the mitochondria need to consume a non-zero amount of resources
to produce a net energy output and each mitochondrion comes with a maintenance cost.
D) The total energy produced by wildtypes increases when mutants are present. E) When
demand is satisfied, the cost increases with w in the linear model, resulting in minimal costs
when copy numbers attain the minimum number required to satisfy demand (1). In contrast,
for the saturating model the cost decreases at first because as individual resource consumption
drops, the energy production efficiency increases. Minimum cost now occurs when mitochon-
dria are working most efficiently (2). Parameters �1 = 0.1 and �2 = 1.0 were used.
(EPS)
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S3 Fig. Changing mutant efficiency (�2) does not lead to expensive intermediate hetero-
plasmies. A), B) Similar to Fig 2 in the main text, these figures show the cost values in (w, m)
space, but now as a function of �2 (mutant efficiency) instead of �1. This time we show the cost
in the entire space. The white lines show the region in which demand is satisfied for our default
parameter values. Because mutants consume the same amount of resource as wildtypes (�1 =
1), resource becomes limiting at relatively low values of m compared to when �1 < 1. Note that
intermediate heteroplasmies are not less efficient here.
(EPS)
S4 Fig. Intermediate h values require more resources to satisfy demand, but only if
mutants consume less resources. A) The resource consumption rates and energy produc-
tion rates of wildtypes and mutants are shown for two states: (w1, m1, h1) = (9000, 1000, 0.1)
and (w2, m2, h2) = (7000, 3000, 0.3). In both cases, the total energy output is equal to the
demand. When heteroplasmy is higher (h = 0.3), the individual resource consumption
rates are higher in order to maintain a constant total energy output. Overall, the state with
h = 0.1 uses the least resources (Eq. (20) in S1 File). �1 = 0.35 was used. B) This figure is simi-
lar to figure (D) but now the two states (w1, m1, h1) = (3000, 7000, 0.7) and (w2, m2, h2) =
(1000, 9000, 0.9) are compared. The state with h = 0.9 uses the least resources (Eq. (21) in
S1 File).
(EPS)
S5 Fig. The existence of intermediate heteroplasmy values is a robust feature of the satu-
rating output model. We show the value of hmax, the most expensive heteroplasmy value at
constant copy number, as a function of total copy number and �1 (describing mutant pathol-
ogy). White regions correspond to hmax = 1. A) Using our default parameter values, an inter-
mediate hmax exists for large enough mutant functionality �1. B) The parameter smax is
increased by 50% with minimal effect on the output. We kept the parameter k fixed as it
defines the amount of proton leak (the resource consumption rate at zero energy output)
which agrees with the amount of proton leak in the linear output model whose parameters are
based on experimental data. C) The parameter ρ1 is increased by an order of magnitude with
minimal effect on the output. D) The parameter ρ1 is increased by an order of magnitude and
smax is decreased by 50%. Again, change in hmax are small.
(EPS)
S6 Fig. Wildtype, mutant and cost dynamics for four different control strategies. Dynamics
are shown for the four controls I, II, III, and IV defined in Table 3 in S1 File. Again, we see that
the effects of the control are more noticeable in low copy number cells. Parameters are set as
given in Table 3 in S1 File. Values for wopt are those for the saturating output model at low and
high copy number. The free parameters in control III and IV (δ and η) were optimised over
initial conditions in the range h 2 [0, 0.2]. For the optimization the default cost function
parameters were used as well as �1 = 0.3.
(EPS)
S7 Fig. At long times and high heteroplasmies, energy sensing control becomes subopti-
mal. The optimal value of δ in a linear feedback control is shown as a function of �1. Here we
used T = 104 days (optimization time) and low copy numbers for both the linear and saturating
model. The solid and dashed lines correspond to trajectories starting at h0 = 0.1 and h0 = 0.8,
respectively. The less resources the mutants consume (and the less output they therefore pro-
duce) the lower their optimal contribution to the control.
(EPS)
Energetic costs and control of mitochondrial DNA populations
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007023 June 26, 2019 20 / 27
S8 Fig. Zinc finger nuclease concentrations for short and long treatments. A) Here we
show the concentration of mitochondrially targeted Zinc Fingers as modelled by Eq (9) in the
main text. The parameter values for the short and strong treatment illustrated here (I0 = 36,
b = 11) are similar to those found in fitting the model to the data. For the mtZFN degradation
rate we used μZ = log(2) day−1 (corresponding to a mtZFN half-life of 1 day). There exists a
possibility of increasing heteroplasmy levels through treatment. B) The probability of
increasing heteroplasmy above its initial pre-treatment value h0, after one round of treatment
and recovery, is shown as a function of h0 and ξ. Cells are initialised with a total copy number
of 500. The cross indicates the parameters used in figure (D). The parameter values for I0, b
and c1 are fixed at: (I0, b, c1)� (39, 20, 3 × 10−4); these values provide good fits to experimental
data when assuming a total initial copy number of 500. We used δ = 1. C) Similar to figure (B),
but now cells are initialised with a total copy number of 5000; in these large copy number cells
stochastic fluctuations in copy number have less effect and the probabilities of exceeding initial
heteroplasmy values are smaller compared to figure (B). D) An example of a distribution of
post-treatment heteroplasmy values is shown using parameters h0 and ξ as indicated by the
cross in figure (B). The orange line indicates the value of h0 (the heteroplasmy that was present
before the treatment started).
(EPS)
S9 Fig. mtZFN expression profile during transient transfection of 143B cells. A) Here we
show a schematic of the experiments involving i) transient transfection of high-heteroplasmy
cells with plasmids expressing mtZFN monomers and fluorescent marker proteins, ii) FACS-
based selection of cells expressing both mtZFN monomers (NARPd(+) and COMPa(-)), and
iii) phenotypic evaluation of treated cells. Technical details are provided in Ref. [35]. B) West-
ern blots showing the mtZFN expression profile indicate that the mtZFNs are almost undetect-
able at 96 hours post-transfection, and completely undetectable at 120 hours. Details of the
protocol are provided in Ref. [35].
(EPS)
S10 Fig. Posterior mtZFN treatment parameter distributions. Here we show our posterior
distributions obtained after running our MCMC algorithm (left) as well as the corresponding
sample values (right). Prior distributions are provided in the text. The posterior of log10 b is
cut off due to a degeneracy in our model (Eq. (22) in S1 File), which does not affect our model
predictions.
(EPS)
S11 Fig. Predictions of mtZFN expression are broadly consonant with experimental data.
Drawing from our posterior distributions for I0 and b obtained through Metropolis sampling,
we show 50% and 95% credible intervals of our predicted mtZFN expression profile (solid
black line denotes the maximum a posteriori (MAP) estimate). Data points are obtained
through quantification of the western blots shown in S9B Fig and were subsequently rescaled
to investigate whether our model can broadly account for the experimentally observed dynam-
ics (our predicted mtZFN concentrations are proportional to the measurement data points
with an arbitrary proportionality constant).
(EPS)
S1 Table. Analytical expressions for the means and variances according to the linear noise
approximation. Solutions are shown for wildtype, mutant, and heteroplasmy variances for
various types of control. Dots indicate constant or exponentially decaying terms; full solutions
are provided in Eqs. (11)–(13) in S1 File. Note that the initial rate of increase of heteroplasmy
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variance only depends on mtDNA copy number and turnover (see also [38]).
(EPS)
S2 Table. Parameters used in our mitochondrial cost function with their descriptions.
Parameter values are derived and motivated in Section 4 in S1 File. In this table, ‘high’ and
‘low’ refer to high and low copy numbers, respectively, and the abbreviations ‘sat.’ and ‘lin.’ are
used to indicate our saturating and linear output models.
(EPS)
S3 Table. Parameter values for the four different control mechanisms we employ. Two
parameters of each control are set by the two constraints we impose. The parameter αR was
proposed to lie in the range 5-17 [40] and here we used αR = 10. The values for δ and η are
found by optimizing our cost function over the steady states corresponding to our initial con-
ditions. We used 50 initial conditions equally spread over the range h0 2 [0, 0.2]. The two val-
ues used for wopt are 1524 and 7616 (Table 2 in S1 File). We further use μ = 0.07 day−1.
(EPS)
S1 File. Supporting text.
(PDF)
Author Contributions
Conceptualization: Hanne Hoitzing.
Data curation: Payam A. Gammage, Lindsey Van Haute, Michal Minczuk.
Formal analysis: Hanne Hoitzing.
Supervision: Iain G. Johnston, Nick S. Jones.
Visualization: Hanne Hoitzing.
Writing – original draft: Hanne Hoitzing.
Writing – review & editing: Hanne Hoitzing, Payam A. Gammage, Michal Minczuk, Iain G.
Johnston, Nick S. Jones.
References
1. Laar V. S. V. and Berman S. B. Mitochondrial dynamics in parkinson’s disease. Exp Neurol 218(2),
247–256 (2009). https://doi.org/10.1016/j.expneurol.2009.03.019 PMID: 19332061
2. Liesa M., Palacı´n M., and Zorzano A. Mitochondrial dynamics in mammalian health and disease. Phy-
siol Rev 89(3), 799–845 (2009). https://doi.org/10.1152/physrev.00030.2008 PMID: 19584314
3. Grandemange S., Herzig S., and Martinou J.-C. Mitochondrial dynamics and cancer. Semin Cancer
Biol 19(1), 50–56 (2009). https://doi.org/10.1016/j.semcancer.2008.12.001 PMID: 19138741
4. Zhu X., Perry G., Smith M. A., and Wang X. Abnormal mitochondrial dynamics in the pathogenesis of
alzheimer’s disease. J Alzheimers Dis 33, S253–S262 (2013). https://doi.org/10.3233/JAD-2012-
129005 PMID: 22531428
5. Chan D. C. Fusion and fission: Interlinked processes critical for mitochondrial health. Annu Rev Genet
46(1), 265–287 (2012). https://doi.org/10.1146/annurev-genet-110410-132529 PMID: 22934639
6. Chen H. and Chan D. C. Mitochondrial dynamics—fusion, fission, movement, and mitophagy—in
neurodegenerative diseases. Hum Mol Genet 18(R2), R169–R176 (2009). https://doi.org/10.1093/
hmg/ddp326 PMID: 19808793
7. Hayashi J.-L., Ohta S., Kikuchi A., Takemitsu M., Goto Y.-i., and Nonaka I. Introduction of disease-
related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial
dysfunction. Proceedings of the National Academy of Sciences 88(23), 10614–10618 (1991). https://
doi.org/10.1073/pnas.88.23.10614
Energetic costs and control of mitochondrial DNA populations
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007023 June 26, 2019 22 / 27
8. Rossignol R., Faustin B., Rocher C., Malgat M., Mazat J.-P., and Letellier T. Mitochondrial threshold
effects. Biochemical Journal 370(3), 751–762 (2003). https://doi.org/10.1042/BJ20021594 PMID:
12467494
9. Attardi G., Yoneda M., and Chomyn A. Complementation and segregation behavior of disease-causing
mitochondrial DNA mutations in cellular model systems. Biochimica et Biophysica Acta (BBA)-Molecu-
lar Basis of Disease 1271(1), 241–248 (1995). https://doi.org/10.1016/0925-4439(95)00034-2
10. Boulet L., Karpati G., and Shoubridge E. Distribution and threshold expression of the tRNA (Lys) muta-
tion in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibers (MERRF). American
journal of human genetics 51(6), 1187 (1992). PMID: 1334369
11. Nakada K., Inoue K., Ono T., Isobe K., Ogura A., Goto Y.-i., Nonaka I., and Hayashi J.-I. Inter-mitochon-
drial complementation: mitochondria-specific system preventing mice from expression of disease phe-
notypes by mutant mtDNA. Nature medicine 7(8), 934–940 (2001). https://doi.org/10.1038/90976
PMID: 11479626
12. Moraes C. T. and Schon E. A. [44] detection and analysis of mitochondrial DNA and RNA in muscle by
in situ hybridization and single-fiber pcr. Methods in enzymology 264, 522–540 (1996). https://doi.org/
10.1016/S0076-6879(96)64046-4
13. Sciacco M., Bonilla E., Schon E. A., DiMauro S., and Moraes C. T. Distribution of wild-type and common
deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochon-
drial myopathy. Human Molecular Genetics 3(1), 13–19 (1994). https://doi.org/10.1093/hmg/3.1.13
PMID: 8162014
14. Russell O. and Turnbull D. Mitochondrial DNA disease—molecular insights and potential routes to a
cure. Experimental cell research 325(1), 38–43 (2014). https://doi.org/10.1016/j.yexcr.2014.03.012
PMID: 24675282
15. Durham S. E., Samuels D. C., Cree L. M., and Chinnery P. F. Normal levels of wild-type mitochondrial
DNA maintain cytochrome c oxidase activity for two pathogenic mitochondrial DNA mutations but not
for m. 3243a! g. The American Journal of Human Genetics 81(1), 189–195 (2007). https://doi.org/10.
1086/518901 PMID: 17564976
16. Gitschlag B. L., Kirby C. S., Samuels D. C., Gangula R. D., Mallal S. A., and Patel M. R. Homeostatic
responses regulate selfish mitochondrial genome dynamics in c. elegans. bioRxiv, 050930 (2016).
17. Posakony J. W., England J. M., and Attardi G. Mitochondrial growth and division during the cell cycle in
hela cells. The Journal of cell biology 74(2), 468–491 (1977). https://doi.org/10.1083/jcb.74.2.468
PMID: 885911
18. Jajoo R., Jung Y., Huh D., Viana M. P., Rafelski S. M., Springer M., and Paulsson J. Accurate concen-
tration control of mitochondria and nucleoids. Science 351 (6269), 169–172 (2016). https://doi.org/10.
1126/science.aaa8714 PMID: 26744405
19. Otten A. B., Theunissen T. E., Derhaag J. G., Lambrichs E. H., Boesten I. B., Winandy M., van Mon-
tfoort A. P., Tarbashevich K., Raz E., Gerards M., et al. Differences in strength and timing of the mtDNA
bottleneck between zebrafish germline and non-germline cells. Cell Reports 16(3), 622–630 (2016).
https://doi.org/10.1016/j.celrep.2016.06.023 PMID: 27373161
20. Tang Y., Schon E. A., Wilichowski E., Vazquez-Memije M. E., Davidson E., and King M. P. Rearrange-
ments of human mitochondrial DNA (mtDNA): new insights into the regulation of mtDNA copy number
and gene expression. Molecular biology of the cell 11(4), 1471–1485 (2000). https://doi.org/10.1091/
mbc.11.4.1471 PMID: 10749943
21. Diaz F., Bayona-Bafaluy M. P., Rana M., Mora M., Hao H., and Moraes C. T. Human mitochondrial
DNA with large deletions repopulates organelles faster than full-length genomes under relaxed copy
number control. Nucleic acids research 30(21), 4626–4633 (2002). https://doi.org/10.1093/nar/gkf602
PMID: 12409452
22. Kowald A. and Kirkwood T. B. Transcription could be the key to the selection advantage of mitochon-
drial deletion mutants in aging. Proceedings of the National Academy of Sciences 111(8), 2972–2977
(2014). https://doi.org/10.1073/pnas.1314970111
23. Burgstaller J. P., Johnston I. G., and Poulton J. Mitochondrial dna disease and developmental implica-
tions for reproductive strategies. Molecular human reproduction 21(1), 11–22 (2015). https://doi.org/10.
1093/molehr/gau090 PMID: 25425607
24. Røyrvik E., Burgstaller J. P., and Johnston I. G. mtDNA diversity in human populations highlights the
merit of haplotype matching in gene therapies. Molecular Human Reproduction 22(11), 809–817
(2016). https://doi.org/10.1093/molehr/gaw062 PMID: 27609757
25. Kim Y.-G., Cha J., and Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok i cleav-
age domain. Proceedings of the National Academy of Sciences 93(3), 1156–1160 (1996). https://doi.
org/10.1073/pnas.93.3.1156
Energetic costs and control of mitochondrial DNA populations
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007023 June 26, 2019 23 / 27
26. Urnov F. D., Miller J. C., Lee Y.-L., Beausejour C. M., Rock J. M., Augustus S., Jamieson A. C., Porteus
M. H., Gregory P. D., and Holmes M. C. Highly efficient endogenous human gene correction using
designed zinc-finger nucleases. Nature 435 (7042), 646–651 (2005). https://doi.org/10.1038/
nature03556 PMID: 15806097
27. Bibikova M., Golic M., Golic K. G., and Carroll D. Targeted chromosomal cleavage and mutagenesis in
drosophila using zinc-finger nucleases. Genetics 161(3), 1169–1175 (2002). PMID: 12136019
28. Christian M., Cermak T., Doyle E. L., Schmidt C., Zhang F., Hummel A., Bogdanove A. J., and Voytas
D. F. Targeting dna double-strand breaks with tal effector nucleases. Genetics 186(2), 757–761
(2010). https://doi.org/10.1534/genetics.110.120717 PMID: 20660643
29. Li T., Huang S., Zhao X., Wright D. A., Carpenter S., Spalding M. H., Weeks D. P., and Yang B. Modu-
larly assembled designer tal effector nucleases for targeted gene knockout and gene replacement in
eukaryotes. Nucleic acids research, gkr188 (2011).
30. Miller J. C., Tan S., Qiao G., Barlow K. A., Wang J., Xia D. F., Meng X., Paschon D. E., Leung E., Hink-
ley S. J., et al. A TALE nuclease architecture for efficient genome editing. Nature biotechnology 29(2),
143–148 (2011). https://doi.org/10.1038/nbt.1755 PMID: 21179091
31. Joung J. K. and Sander J. D. TALENs: a widely applicable technology for targeted genome editing.
Nature reviews Molecular cell biology 14(1), 49–55 (2013). https://doi.org/10.1038/nrm3486 PMID:
23169466
32. Bacman S. R., Williams S. L., Pinto M., Peralta S., and Moraes C. T. Specific elimination of mutant mito-
chondrial genomes in patient-derived cells by mitoTALENs. Nature Medicine 19(9), 1111–1113 (2013).
https://doi.org/10.1038/nm.3261 PMID: 23913125
33. Reddy P., Ocampo A., Suzuki K., Luo J., Bacman S. R., Williams S. L., Sugawara A., Okamura D., Tsu-
nekawa Y., Wu J., Lam D., Xiong X., Montserrat N., Esteban C. R., Liu G.-H., Sancho-Martinez I.,
Manau D., Civico S., Cardellach F., del Mar O’Callaghan M., Campistol J., Zhao H., Campistol J. M.,
Moraes C. T., and Belmonte J. C. I. Selective elimination of mitochondrial mutations in the germline by
genome editing. Cell 161(3), 459–469 (2015). https://doi.org/10.1016/j.cell.2015.03.051 PMID:
25910206
34. Bacman S. R., Williams S. L., Pinto M., and Moraes C. T. The use of mitochondria-targeted endonucle-
ases to manipulate mtDNA. Methods in enzymology 547, 373 (2014). https://doi.org/10.1016/B978-0-
12-801415-8.00018-7 PMID: 25416366
35. Gammage P. A., Van Haute L., and Minczuk M. Engineered mtZFNs for manipulation of human mito-
chondrial DNA heteroplasmy. Mitochondrial DNA: Methods and Protocols, 145–162 (2016). https://doi.
org/10.1007/978-1-4939-3040-1_11
36. Gammage P. A., Gaude E., Van Haute L., Rebelo-Guiomar P., Jackson C. B., Rorbach J., Pekalski M.
L., Robinson A. J., Charpentier M., Concordet J.-P., et al. Near-complete elimination of mutant mtDNA
by iterative or dynamic dose-controlled treatment with mtZFNs. Nucleic Acids Research, 7804–7816
(2016). https://doi.org/10.1093/nar/gkw676 PMID: 27466392
37. Hashimoto M., Bacman S. R., Peralta S., Falk M. J., Chomyn A., Chan D. C., Williams L. S., and Moraes
C. T. Mitotalen: A general approach to reduce mutant mtDNA loads and restore oxidative phosphoryla-
tion function in mitochondrial diseases. Molecular Therapy (2015). https://doi.org/10.1038/mt.2015.126
38. Johnston I. G. and Jones N. S. Evolution of cell-to-cell variability in stochastic, controlled, heteroplasmic
mtdna populations. The American Journal of Human Genetics 99(5), 1150–1162 (2016). https://doi.
org/10.1016/j.ajhg.2016.09.016 PMID: 27843124
39. Gross N. J., Getz G. S., and Rabinowitz M. Apparent turnover of mitochondrial deoxyribonucleic acid
and mitochondrial phospholipids in the tissues of the rat. Journal of Biological Chemistry 244(6), 1552–
1562 (1969). PMID: 5773057
40. Chinnery P. F. and Samuels D. C. Relaxed replication of mtDNA: a model with implications for the
expression of disease. The American Journal of Human Genetics 64(4), 1158–1165 (1999). https://doi.
org/10.1086/302311 PMID: 10090901
41. Capps G. J., Samuels D. C., and Chinnery P. F. A model of the nuclear control of mitochondrial DNA
replication. Journal of theoretical biology 221(4), 565–583 (2003). https://doi.org/10.1006/jtbi.2003.
3207 PMID: 12713941
42. Elson J., Samuels D., Turnbull D., and Chinnery P. Random intracellular drift explains the clonal expan-
sion of mitochondrial DNA mutations with age. The American Journal of Human Genetics 68(3), 802–
806 (2001). https://doi.org/10.1086/318801 PMID: 11179029
43. Kowald A. and Kirkwood T. B. Mitochondrial mutations and aging: random drift is insufficient to explain
the accumulation of mitochondrial deletion mutants in short-lived animals. Aging cell 12(4), 728–731
(2013). https://doi.org/10.1111/acel.12098 PMID: 23742009
44. Lill R., Hoffmann B., Molik S., Pierik A. J., Rietzschel N., Stehling O., Uzarska M. A., Webert H., Wil-
brecht C., and Mu¨hlenhoff U. The role of mitochondria in cellular iron–sulfur protein biogenesis and iron
Energetic costs and control of mitochondrial DNA populations
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007023 June 26, 2019 24 / 27
metabolism. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1823(9), 1491–1508
(2012). https://doi.org/10.1016/j.bbamcr.2012.05.009
45. Wang C. and Youle R. J. The role of mitochondria in apoptosis. Annual review of genetics 43, 95
(2009). https://doi.org/10.1146/annurev-genet-102108-134850 PMID: 19659442
46. Rizzuto R., De Stefani D., Raffaello A., and Mammucari C. Mitochondria as sensors and regulators of
calcium signalling. Nature reviews Molecular cell biology 13(9), 566–578 (2012). https://doi.org/10.
1038/nrm3412 PMID: 22850819
47. Mora´n M., Moreno-Lastres D., Marı´n-Buera L., Arenas J., Martı´n M. A., and Ugalde C. Mitochondrial
respiratory chain dysfunction: implications in neurodegeneration. Free Radical Biology and Medicine
53(3), 595–609 (2012). https://doi.org/10.1016/j.freeradbiomed.2012.05.009 PMID: 22595027
48. Monternier P.-A., Marmillot V., Rouanet J.-L., and Roussel D. Mitochondrial phenotypic flexibility
enhances energy savings during winter fast in king penguin chicks. Journal of Experimental Biology
217(15), 2691–2697 (2014). https://doi.org/10.1242/jeb.104505 PMID: 24803465
49. Salin K., Roussel D., Rey B., and Voituron Y. David and Goliath: a mitochondrial coupling problem?
Journal of Experimental Zoology Part A: Ecological Genetics and Physiology 317(5), 283–293 (2012).
https://doi.org/10.1002/jez.1722
50. Brand M. D., Harper M.-E., and Taylor H. C. Control of the effective P/O ratio of oxidative phosphoryla-
tion in liver mitochondria and hepatocytes. Biochemical Journal 291(3), 739–748 (1993). https://doi.
org/10.1042/bj2910739 PMID: 8489502
51. Yadava N. and Nicholls D. G. Spare respiratory capacity rather than oxidative stress regulates gluta-
mate excitotoxicity after partial respiratory inhibition of mitochondrial complex i with rotenone. The Jour-
nal of neuroscience 27(27), 7310–7317 (2007). https://doi.org/10.1523/JNEUROSCI.0212-07.2007
PMID: 17611283
52. Hill B. G., Dranka B. P., Zou L., Chatham J. C., and Darley-Usmar V. M. Importance of the bioenergetic
reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenal. Biochemical Jour-
nal 424(1), 99–107 (2009). https://doi.org/10.1042/BJ20090934 PMID: 19740075
53. Pfeiffer T., Schuster S., and Bonhoeffer S. Cooperation and competition in the evolution of atp-produc-
ing pathways. Science 292 (5516), 504–507 (2001). https://doi.org/10.1126/science.1058079 PMID:
11283355
54. Angulo-Brown F., Santilla´n M., and Calleja-Quevedo E. Thermodynamic optimality in some biochemical
reactions. Il Nuovo Cimento D 17(1), 87–90 (1995). https://doi.org/10.1007/BF02451604
55. Waddell T. G., Repovic P., Mele´ndez-Hevia E., Heinrich R., and Montero F. Optimization of glycolysis:
new discussions. Biochemistry and Molecular Biology Education 27(1), 12–13 (1999).
56. van Dijken J. P., Weusthuis R. A., and Pronk J. T. Kinetics of growth and sugar consumption in yeasts.
Antonie van leeuwenhoek 63(3-4), 343–352 (1993). https://doi.org/10.1007/BF00871229 PMID:
8279829
57. Sriskanthadevan S., Jeyaraju D. V., Chung T. E., Prabha S., Xu W., Skrtic M., Jhas B., Hurren R.,
Gronda M., Wang X., et al. Aml cells have low spare reserve capacity in their respiratory chain that ren-
ders them susceptible to oxidative metabolic stress. Blood 125(13), 2120–2130 (2015). https://doi.org/
10.1182/blood-2014-08-594408 PMID: 25631767
58. Pfleger J., He M., and Abdellatif M. Mitochondrial complex ii is a source of the reserve respiratory capac-
ity that is regulated by metabolic sensors and promotes cell survival. Cell death & disease 6(7), e1835
(2015). https://doi.org/10.1038/cddis.2015.202
59. Sharpley M. S., Marciniak C., Eckel-Mahan K., McManus M., Crimi M., Waymire K., Lin C. S., Masubu-
chi S., Friend N., Koike M., et al. Heteroplasmy of mouse mtDNA is genetically unstable and results in
altered behavior and cognition. Cell 151(2), 333–343 (2012). https://doi.org/10.1016/j.cell.2012.09.004
PMID: 23063123
60. Minczuk M., Papworth M. A., Kolasinska P., Murphy M. P., and Klug A. Sequence-specific modification
of mitochondrial DNA using a chimeric zinc finger methylase. Proceedings of the National Academy of
Sciences 103(52), 19689–19694 (2006). https://doi.org/10.1073/pnas.0609502103
61. Minczuk M., Papworth M. A., Miller J. C., Murphy M. P., and Klug A. Development of a single-chain,
quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA.
Nucleic acids research 36(12), 3926–3938 (2008). https://doi.org/10.1093/nar/gkn313 PMID:
18511461
62. Gammage P. A., Rorbach J., Vincent A. I., Rebar E. J., and Minczuk M. Mitochondrially targeted ZFNs
for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point
mutations. EMBO molecular medicine 6(4), 458–466 (2014). https://doi.org/10.1002/emmm.
201303672 PMID: 24567072
Energetic costs and control of mitochondrial DNA populations
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007023 June 26, 2019 25 / 27
63. Cree L. M., Samuels D. C., de Sousa Lopes S. C., Rajasimha H. K., Wonnapinij P., Mann J. R., Dahl H.-
H. M., and Chinnery P. F. A reduction of mitochondrial dna molecules during embryogenesis explains
the rapid segregation of genotypes. Nature genetics 40(2), 249–254 (2008). https://doi.org/10.1038/ng.
2007.63 PMID: 18223651
64. Johnston I. G., Burgstaller J. P., Havlicek V., Kolbe T., Ru¨licke T., Brem G., Poulton J., and Jones N. S.
Stochastic modelling, bayesian inference, and new in vivo measurements elucidate the debated
mtDNA bottleneck mechanism. eLife 4, e07464 (2015). https://doi.org/10.7554/eLife.07464 PMID:
26035426
65. Freyer C., Cree L. M., Mourier A., Stewart J. B., Koolmeister C., Milenkovic D., Wai T., Floros V. I., Hag-
stro¨m E., Chatzidaki E. E., et al. Variation in germline mtdna heteroplasmy is determined prenatally but
modified during subsequent transmission. Nature genetics 44(11), 1282–1285 (2012). https://doi.org/
10.1038/ng.2427 PMID: 23042113
66. Stewart J. B. and Chinnery P. F. The dynamics of mitochondrial dna heteroplasmy: implications for
human health and disease. Nature Reviews Genetics 16(9), 530–542 (2015). https://doi.org/10.1038/
nrg3966 PMID: 26281784
67. Kaufmann P., Shanske S., Hirano M., DiMauro S., King M. P., Koga Y., and Schon E. A. Mitochondrial
DNA and RNA processing in melas. Annals of neurology 40(2), 172–180 (1996). https://doi.org/10.
1002/ana.410400208 PMID: 8773598
68. Shoubridge E. A., Karpati G., and Hastings K. E. Deletion mutants are functionally dominant over wild-
type mitochondrial genomes in skeletal muscle fiber segments in mitochondrial disease. Cell 62(1),
43–49 (1990). https://doi.org/10.1016/0092-8674(90)90238-A PMID: 2163769
69. Moraes C. T., Ricci E., Petruzzella V., Shanske S., DiMauro S., Schon E. A., and Bonilla E. Molecular
analysis of the muscle pathology associated with mitochondrial DNA deletions. Nature genetics 1(5),
359–367 (1992). https://doi.org/10.1038/ng0892-359 PMID: 1284549
70. Tokunaga M., Mita S., Murakami T., Kumamoto T., Uchino M., Nonaka I., and Ando M. Single muscle
fiber analysis of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes
(melas). Annals of neurology 35(4), 413–419 (1994). https://doi.org/10.1002/ana.410350407 PMID:
8154867
71. Nicholas A., Kraytsberg Y., Guo X., and Khrapko K. On the timing and the extent of clonal expansion of
mtDNA deletions: evidence from single-molecule pcr. Experimental neurology 218(2), 316–319 (2009).
https://doi.org/10.1016/j.expneurol.2009.04.029 PMID: 19426731
72. Schwarze S. R., Lee C. M., Chung S. S., Roecker E. B., Weindruch R., and Aiken J. M. High levels of
mitochondrial DNA deletions in skeletal muscle of old rhesus monkeys. Mechanisms of ageing and
development 83(2), 91–101 (1995). https://doi.org/10.1016/0047-6374(95)01611-3 PMID: 8569289
73. Reznik E., Miller M. L., Şenbabaoğlu Y., Riaz N., Sarungbam J., Tickoo S. K., Al-Ahmadie H. A., Lee
W., Seshan V. E., Hakimi A. A., et al. Mitochondrial DNA copy number variation across human cancers.
eLife 5, e10769 (2016). https://doi.org/10.7554/eLife.10769 PMID: 26901439
74. Majamaa-Voltti K., Peuhkurinen K., Kortelainen M.-L., Hassinen I. E., and Majamaa K. Cardiac abnor-
malities in patients with mitochondrial DNA mutation 3243A>G. BMC cardiovascular disorders 2(1), 12
(2002). https://doi.org/10.1186/1471-2261-2-12 PMID: 12150714
75. Ciafaloni E., Ricci E., Servidei S., Shanske S., Silvestri G., Manfredi G., Schon E., and DiMauro S.
Widespread tissue distribution of a trnaleu (uur) mutation in the mitochondrial DNA of a patient with
melas syndrome. Neurology 41(10), 1663–1663 (1991). https://doi.org/10.1212/wnl.41.10.1663 PMID:
1922812
76. Anan R., Nakagawa M., Miyata M., Higuchi I., Nakao S., Suehara M., Osame M., and Tanaka H. Car-
diac involvement in mitochondrial diseases a study on 17 patients with documented mitochondrial DNA
defects. Circulation 91(4), 955–961 (1995). https://doi.org/10.1161/01.CIR.91.4.955 PMID: 7850981
77. Jeppesen T. D., Schwartz M., Olsen D. B., and Vissing J. Oxidative capacity correlates with muscle
mutation load in mitochondrial myopathy. Annals of Neurology 54(1), 86–92 (2003). https://doi.org/10.
1002/ana.10594 PMID: 12838523
78. Stein L. R. and Imai S.-i. The dynamic regulation of nad metabolism in mitochondria. Trends in Endocri-
nology & Metabolism 23(9), 420–428 (2012). https://doi.org/10.1016/j.tem.2012.06.005
79. Alano C. C., Ying W., and Swanson R. A. Poly (adp-ribose) polymerase-1-mediated cell death in astro-
cytes requires NAD+ depletion and mitochondrial permeability transition. Journal of Biological Chemis-
try 279(18), 18895–18902 (2004). https://doi.org/10.1074/jbc.M313329200 PMID: 14960594
80. Bai P., Canto´ C., Oudart H., Brunya´nszki A., Cen Y., Thomas C., Yamamoto H., Huber A., Kiss B.,
Houtkooper R. H., et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activa-
tion. Cell Metabolism 13(4), 461–468 (2011). https://doi.org/10.1016/j.cmet.2011.03.004 PMID:
21459330
Energetic costs and control of mitochondrial DNA populations
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007023 June 26, 2019 26 / 27
81. Pittelli M., Felici R., Pitozzi V., Giovannelli L., Bigagli E., Cialdai F., Romano G., Moroni F., and Chiarugi
A. Pharmacological effects of exogenous nad on mitochondrial bioenergetics, DNA repair, and apopto-
sis. Molecular pharmacology 80(6), 1136–1146 (2011). https://doi.org/10.1124/mol.111.073916 PMID:
21917911
82. Korzeniewski B., Harper M.-E., and Brand M. D. Proportional activation coefficients during stimulation
of oxidative phosphorylation by lactate and pyruvate or by vasopressin. Biochimica et Biophysica Acta
(BBA)-Bioenergetics 1229(3), 315–322 (1995). https://doi.org/10.1016/0005-2728(95)00008-7
83. Nobes C., Hay W., and Brand M. The mechanism of stimulation of respiration by fatty acids in isolated
hepatocytes. Journal of Biological Chemistry 265(22), 12910–12915 (1990). PMID: 2376580
84. Affourtit C. and Brand M. D. Uncoupling protein-2 contributes significantly to high mitochondrial proton
leak in INS-1E insulinoma cells and attenuates glucose-stimulated insulin secretion. Biochemical Jour-
nal 409(1), 199–204 (2008). https://doi.org/10.1042/BJ20070954 PMID: 17824844
85. Michikawa Y., Mazzucchelli F., Bresolin N., Scarlato G., and Attardi G. Aging-dependent large accumu-
lation of point mutations in the human mtDNA control region for replication. Science 286 (5440), 774–
779 (1999). https://doi.org/10.1126/science.286.5440.774 PMID: 10531063
86. Wallace D. C.Mitochondrial genetics: a paradigm for aging and degenerative diseases?Science 256
(5057), 628 (1992).
87. Kowald A. and Klipp E. Mathematical models of mitochondrial aging and dynamics. Prog Mol Biol Transl
Sci 127, 63–92 (2014). https://doi.org/10.1016/B978-0-12-394625-6.00003-9 PMID: 25149214
88. Yoneda M., Chomyn A., Martinuzzi A., Hurko O., and Attardi G. Marked replicative advantage of human
mtDNA carrying a point mutation that causes the melas encephalomyopathy. Proceedings of the
National Academy of Sciences 89(23), 11164–11168 (1992). https://doi.org/10.1073/pnas.89.23.
11164
89. Kowald A. and Kirkwood T. B. Accumulation of defective mitochondria through delayed degradation of
damaged organelles and its possible role in the ageing of post-mitotic and dividing cells. Journal of theo-
retical biology 202(2), 145–160 (2000). https://doi.org/10.1006/jtbi.1999.1046 PMID: 10640434
90. Twig G., Elorza A., Molina A. J., Mohamed H., Wikstrom J. D., Walzer G., Stiles L., Haigh S. E., Katz S.,
Las G., et al. Fission and selective fusion govern mitochondrial segregation and elimination by autop-
hagy. The EMBO journal 27(2), 433–446 (2008). https://doi.org/10.1038/sj.emboj.7601963 PMID:
18200046
91. Busch K. B., Kowald A., and Spelbrink J. N. Quality matters: how does mitochondrial network dynamics
and quality control impact on mtDNA integrity? Philosophical Transactions of the Royal Society B: Bio-
logical Sciences 369 (1646), 20130442 (2014). https://doi.org/10.1098/rstb.2013.0442
92. Poovathingal S. K., Gruber J., Halliwell B., and Gunawan R. Stochastic drift in mitochondrial DNA point
mutations: a novel perspective ex silico. PLoS computational biology 5(11), e1000572 (2009). https://
doi.org/10.1371/journal.pcbi.1000572 PMID: 19936024
93. Johnston I. G. and Jones N. S. Closed-form stochastic solutions for non-equilibrium dynamics and
inheritance of cellular components over many cell divisions. In Proc. R. Soc. A, volume 471, 20150050.
The Royal Society, (2015).
94. Salvatier J., Wiecki T. V., and Fonnesbeck C. Probabilistic programming in python using pymc3. PeerJ
Computer Science 2, e55 (2016). https://doi.org/10.7717/peerj-cs.55
Energetic costs and control of mitochondrial DNA populations
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007023 June 26, 2019 27 / 27
